FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095255766> ?p ?o ?g. }

• W2095255766 endingPage "326" @default.
• W2095255766 startingPage "319" @default.
• W2095255766 abstract "Although imatinib is presently the treatment of choice in newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) patients, 8 years from start of the International Randomized Study of Interferon and STI571 (IRIS) trial, 45% of the patients originally enrolled in the imatinib arm (imatinib 400 mg/d) have discontinued this treatment; in 15% of the cases this was due to lack of efficacy and in 5% for safety or intolerance problems. With the aim of improving the results of the standard imatinib 400 mg/d first-line therapy of CML, several trials have been started and are presently ongoing. The purpose of these trials is to test the efficacy of higher dosages of imatinib and of imatinib in combination with other agents, in particular with interferon alpha (IFN). In addition, second-generation tyrosine kinase inhibitors (TKIs), which are now available for treatment of patients resistant or intolerant to imatinib, also have been tested for first-line treatment, in the setting of both single-center and multicenter studies. The results of these trials seem to indicate a superior efficacy of the more potent second-generation TKIs with respect to imatinib, particularly in terms of higher rates of complete cytogenetic responses (CCyR) and of major molecular responses (MMR), that, more importantly, also seem to lead to a decreased number of progressions of the disease. Although these results still need to be fully evaluated after a longer period of follow-up, the use of next-generation agents and modified imatinib-based strategies in the first-line therapy of CML is likely to become a key area of clinical research during the next few years." @default.
• W2095255766 created "2016-06-24" @default.
• W2095255766 creator A5019949455 @default.
• W2095255766 creator A5090108654 @default.
• W2095255766 date "2010-10-01" @default.
• W2095255766 modified "2023-09-27" @default.
• W2095255766 title "Can We and Should We Improve on Frontline Imatinib Therapy for Chronic Myeloid Leukemia?" @default.
• W2095255766 cites W1430390330 @default.
• W2095255766 cites W1548924510 @default.
• W2095255766 cites W1799579309 @default.
• W2095255766 cites W1986635169 @default.
• W2095255766 cites W1988399039 @default.
• W2095255766 cites W1990020715 @default.
• W2095255766 cites W1993756686 @default.
• W2095255766 cites W1994220656 @default.
• W2095255766 cites W2007658220 @default.
• W2095255766 cites W2009746825 @default.
• W2095255766 cites W2016953305 @default.
• W2095255766 cites W2016960626 @default.
• W2095255766 cites W2018734495 @default.
• W2095255766 cites W2028959752 @default.
• W2095255766 cites W2046269728 @default.
• W2095255766 cites W2090004346 @default.
• W2095255766 cites W2091005492 @default.
• W2095255766 cites W2095911292 @default.
• W2095255766 cites W2107268345 @default.
• W2095255766 cites W2109163020 @default.
• W2095255766 cites W2116153687 @default.
• W2095255766 cites W2120033838 @default.
• W2095255766 cites W2131656137 @default.
• W2095255766 cites W2135620625 @default.
• W2095255766 cites W2139160856 @default.
• W2095255766 cites W2146658081 @default.
• W2095255766 cites W2148831661 @default.
• W2095255766 cites W2151486690 @default.
• W2095255766 cites W2152713204 @default.
• W2095255766 cites W2166654361 @default.
• W2095255766 cites W2168633862 @default.
• W2095255766 cites W2172189430 @default.
• W2095255766 cites W2261840157 @default.
• W2095255766 cites W2301293935 @default.
• W2095255766 cites W2329648702 @default.
• W2095255766 cites W2530270604 @default.
• W2095255766 cites W2549736790 @default.
• W2095255766 cites W2552717129 @default.
• W2095255766 cites W2558943357 @default.
• W2095255766 cites W2559594280 @default.
• W2095255766 cites W2570312805 @default.
• W2095255766 cites W2574416715 @default.
• W2095255766 cites W2590392935 @default.
• W2095255766 cites W2591760772 @default.
• W2095255766 cites W2593142701 @default.
• W2095255766 cites W2593731468 @default.
• W2095255766 cites W2594322701 @default.
• W2095255766 cites W2596224382 @default.
• W2095255766 cites W3044574244 @default.
• W2095255766 doi "https://doi.org/10.1053/j.seminhematol.2010.06.001" @default.
• W2095255766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20875548" @default.
• W2095255766 hasPublicationYear "2010" @default.
• W2095255766 type Work @default.
• W2095255766 sameAs 2095255766 @default.
• W2095255766 citedByCount "11" @default.
• W2095255766 countsByYear W20952557662015 @default.
• W2095255766 countsByYear W20952557662016 @default.
• W2095255766 countsByYear W20952557662017 @default.
• W2095255766 countsByYear W20952557662019 @default.
• W2095255766 countsByYear W20952557662020 @default.
• W2095255766 crossrefType "journal-article" @default.
• W2095255766 hasAuthorship W2095255766A5019949455 @default.
• W2095255766 hasAuthorship W2095255766A5090108654 @default.
• W2095255766 hasConcept C121608353 @default.
• W2095255766 hasConcept C126322002 @default.
• W2095255766 hasConcept C143998085 @default.
• W2095255766 hasConcept C2777413986 @default.
• W2095255766 hasConcept C2777583451 @default.
• W2095255766 hasConcept C2778729363 @default.
• W2095255766 hasConcept C2778820342 @default.
• W2095255766 hasConcept C2779536868 @default.
• W2095255766 hasConcept C3019892230 @default.
• W2095255766 hasConcept C535046627 @default.
• W2095255766 hasConcept C71924100 @default.
• W2095255766 hasConcept C98274493 @default.
• W2095255766 hasConceptScore W2095255766C121608353 @default.
• W2095255766 hasConceptScore W2095255766C126322002 @default.
• W2095255766 hasConceptScore W2095255766C143998085 @default.
• W2095255766 hasConceptScore W2095255766C2777413986 @default.
• W2095255766 hasConceptScore W2095255766C2777583451 @default.
• W2095255766 hasConceptScore W2095255766C2778729363 @default.
• W2095255766 hasConceptScore W2095255766C2778820342 @default.
• W2095255766 hasConceptScore W2095255766C2779536868 @default.
• W2095255766 hasConceptScore W2095255766C3019892230 @default.
• W2095255766 hasConceptScore W2095255766C535046627 @default.
• W2095255766 hasConceptScore W2095255766C71924100 @default.
• W2095255766 hasConceptScore W2095255766C98274493 @default.
• W2095255766 hasIssue "4" @default.
• W2095255766 hasLocation W20952557661 @default.
• W2095255766 hasLocation W20952557662 @default.
• W2095255766 hasOpenAccess W2095255766 @default.

• next